Search

Search Results

• P047 | ONABOTULINUMTOXIN-A EFFECTIVENESS EVALUATION IN CHRONIC MIGRAINE PATIENTS WITH SHORT OR LONG DISEASE HISTORY AND PSYCHIATRIC COMORBIDITIES: AN ITALIAN MULTICENTRIC STUDY (THE BACH STUDY)

  F. Vernieri^1|2, P. Pasqualetti³, M. Marcosano^1|2, N. Brunelli⁴, L. Fofi¹, D. Antonio Montisano⁵, L. Grazzi⁵, R. Ornello⁶, C. Rosignoli⁶, A. Doretti⁷, E. Colombo⁷, M. Albanese⁸, G. Viticchi⁹, S. Migliore⁶, S. Sacco⁶, C. Altamura^1|2 | ¹Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Section of Health Statistics and Biometry, Department WHES (Wellbeing, Health & Environmental Sustainability), Sapienza University of Rome, Italy; ⁴Department of Neurology, Vall d’Hebron Research Institute, Barcelona, Spain; ⁵Headache Center, IRCCS Fondazione Istituto Neurologico "Carlo Besta", Milano, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁷Department of Systems Medicine, University of Rome Tor Vergata, Italy; ⁸IRCCS Istituto Auxologico Italiano, Milano, Italy; ⁹Neurological Clinic, Experimental and Clinical Medicine Department, Marche Polytechnic University, Ancona, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16003

  • 0 abstract views
  • 0 PDF

• P025 | PAIN RELIEF AFTER 30 MINUTES PREDICTS COMPLETE ACUTE TREATMENT SUCCESS AT 12 HOURS: A REAL-WORLD ANALYSIS OF INTRAVENOUS EPTINEZUMAB INFUSION IN HIGHLY REFRACTORY MIGRAINE PATIENTS

  L. Fofi¹, C. Altamura^1|2, M. Marcosano^1|2, L. d’Onofrio², A. Doretti³, F. Pistoia⁴, A. Granato⁵, S. Guerzoni⁶, M. Trimboli⁷, L. Grazzi⁸, D. Antonio Montisano⁸, G. Avino⁹, G. Sebastianelli¹⁰, C. Fasano¹¹, E. Maria Piella¹², P. Geppetti¹³, N. Brunelli¹, S. Lodico², L. Francesco Iannone¹⁴, F. Vernieri^1|2 | ¹Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; ⁴Department of Biotechnological and Applied Clinical Sciences, Neurological Institute, University of L’Aquila, Italy; ⁵Headache Center, Neurology Clinic, University Hospital of Trieste, University of Trieste, Italy; ⁶Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, Italy; ⁷Azienda Ospedaliera-Universitaria “Renato Dulbecco”, Catanzaro, Italy; ⁸Headache Center, Department of Neurology, IRCCS Foundation “Carlo Besta” Neurological Institute, Milan, Italy; ⁹SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹⁰Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino ICOT, Sapienza University of Rome, Latina, Italy; ¹¹Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence, Italy; ¹²Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Italy; ¹³Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, United States; ¹⁴Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15981

  • 0 abstract views
  • 0 PDF